The FDA’s drug review process can often be "unpredictable," and review teams typically “differ greatly” in what they ask of drug sponsors, Sen. Bill Cassidy said.

South Carolina parents living in the state’s measles epicenter tell Rhian Lubin of their devastation after their unvaccinated ...

More parents are skipping childhood vaccines after the COVID-19 pandemic as vaccines become a flashpoint in American politics and culture. The post How the search for vaccine safety led parents away ...

Wits University says it is developing its own engineered virus-like particle systems to boost vaccine production in South Africa and beyond.

Religious exemptions are driving the number of vaccinated NJ kids down to the lowest number in years, causing officials to worry about disease spread.

(THE CONVERSATION) The Food and Drug Administration’s decision, made public on Feb. 10, 2026, to not review an application to approve Moderna’s proposed mRNA-based flu vaccine set off a firestorm of ...

WASHINGTON, D.C. - The U.S. Food and Drug Administration (FDA) is set to review Moderna's new flu vaccine made with Nobel prize-winning mRNA technology, reversing course after the agency declined ...

The disagreement between Moderna and the FDA has reached a resolution just eight days after the biotech received a Refusal-to ...

Northwestern researchers have shown that when it comes to cancer vaccines, arrangement can be just as important as ingredients. By repositioning a small fragment of an HPV protein on a DNA-based ...

Moderna's stock surges after the FDA said it would review the biotech's flu vaccine candidate, a week after it had refused to do so. Shares of Moderna surged Wednesday after the drugmaker got health ...

The U.S. Food and Drug Administration announced recently that it will not review Moderna’s mRNA flu vaccine, despite late-stage trials showing it was safe and effective. The rejection has many in and ...

Good afternoon, and welcome back to the Health Brief newsletter. I’m coming to you today from the Anthem theater in Washington, D.C., where the pharmaceutical industry is convening to discuss the ...